Arcutis Biotherapeutics
ARQT
ARQT
78 hedge funds and large institutions have $1.15B invested in Arcutis Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.38%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
24
Increased
33
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$39.4M |
| 2 |
BlackRock
New York
|
+$23.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16.1M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.5M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.92M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.76M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.68M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$696K |
